Stoke Therapeutics Inc’s filing revealed that its Director Kaye Edward M. MD unloaded Company’s shares for reported $0.75 million on Oct 08 ’25. In the deal valued at $30.00 per share,25,000 shares were sold. As a result of this transaction, Kaye Edward M. MD now holds 49,124 shares worth roughly $1.48 million.
Then, EDWARD M KAYE bought 25,000 shares, generating $682,750 in total proceeds.
Before that, Kaye Edward M. MD sold 42,461 shares. Stoke Therapeutics Inc shares valued at $1,065,206 were divested by the Director at a price of $25.09 per share. As a result of the transaction, Kaye Edward M. MD now holds 49,124 shares, worth roughly $1.48 million.
Jefferies initiated its Stoke Therapeutics Inc [STOK] rating to a Buy in a research note published on July 18, 2025; the price target was $30. A number of analysts have revised their coverage, including Chardan Capital Markets’s analysts, who began to cover the stock in mid December with a ‘”a Buy”‘ rating. TD Cowen revised its rating on March 26, 2024. It rated STOK as “an Outperform” which previously was an “a Market perform”.
Price Performance Review of STOK
On Friday, Stoke Therapeutics Inc [NASDAQ:STOK] saw its stock jump 0.97% to $30.19. Over the last five days, the stock has gained 18.11%. Stoke Therapeutics Inc shares have risen nearly 145.85% since the year began. Nevertheless, the stocks have risen 173.71% over the past one year.
How much short interest is there in Stoke Therapeutics Inc?
A steep rise in short interest was recorded in Stoke Therapeutics Inc stocks on 2025-09-30, growing by 46775.0 shares to a total of 10.78 million shares. Yahoo Finance data shows the prior-month short interest on 2025-08-29 was 10.74 million shares. There was a rise of 0.43%, which implies that there is a positive sentiment for the stock.
